In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223

References

• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. (1995). Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261–270.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–832.
   PubMed Web of Science ®Google Scholar
• de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. (1990). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387–394.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. (2003). Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12:87–100.
   PubMed Web of Science ®Google Scholar
• Green J, Feinglos M. (2008). New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 4:743–751.
   PubMedGoogle Scholar
• Hebert MF. (1997). Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27:201–214.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. (1992). Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453–457.
   PubMed Web of Science ®Google Scholar
• Holló Z, Homolya L, Hegedüs T, Sarkadi B. (1996). Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383:99–104.
   PubMed Web of Science ®Google Scholar
• Holst JJ. (2004). Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 9:155–166.
   PubMedGoogle Scholar
• Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, Stuart F, Meier-Kriesche HU, Fryer J. (1999). Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 67:333–335.
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2005a). (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141–151.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. (2005b). High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–2658.
   PubMed Web of Science ®Google Scholar
• Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. (2002). Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108–1114.
   PubMed Web of Science ®Google Scholar
• Linder CD, Renaud NA, Hutzler JM. (2009). Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos 37:10–13.
   PubMed Web of Science ®Google Scholar
• Masuda S, Goto M, Kiuchi T, Uemoto S, Kodawara T, Saito H, Tanaka K, Inui K. (2003). Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl 9:1108–1113.
   PubMed Web of Science ®Google Scholar
• McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. (2005). Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128:159–165.
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. (1995). Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158.
   PubMed Web of Science ®Google Scholar
• Nielsen LL. (2005). Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10:703–710.
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552–1562.
   PubMed Web of Science ®Google Scholar
• Rae JM, Soukhova NV, Flockhart DA, Desta Z. (2002). Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525–530.
   PubMed Web of Science ®Google Scholar
• Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. (1990). Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651–663.
   PubMed Web of Science ®Google Scholar
• Smalley J, Kadiyala P, Xin B, Balimane P, Olah T. (2006). Development of an on-line extraction turbulent flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bi-directional assay samples. J Chromatogr B Analyt Technol Biomed Life Sci 830:270–277.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Gaman EA, Obach RS. (2005). Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2003). Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos 31:343.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. (1987). Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029–1036.
   PubMed Web of Science ®Google Scholar
• Weber AE. (2004). Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47:4135–4141.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. (1990). Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207–213.
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. (1995). Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492–497.
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. (2004). Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243–272.
   PubMed Web of Science ®Google Scholar
• Yeo KR, Rostami-Hodjegan A, Tucker GT. (2004). Abundance of cytochrome P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687.
   Web of Science ®Google Scholar
• Yun CH, Shimada T, Guengerich FP. (1991). Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40:679–685.
   PubMed Web of Science ®Google Scholar